Viatris Inc. (VTRS)
| Market Cap | 17.19B |
| Revenue (ttm) | 14.30B |
| Net Income (ttm) | -3.51B |
| Shares Out | 1.15B |
| EPS (ttm) | -3.00 |
| PE Ratio | n/a |
| Forward PE | 6.12 |
| Dividend | $0.48 (3.15%) |
| Ex-Dividend Date | Mar 9, 2026 |
| Volume | 22,028,078 |
| Open | 15.16 |
| Previous Close | 15.25 |
| Day's Range | 14.85 - 15.50 |
| 52-Week Range | 6.85 - 16.47 |
| Beta | 0.80 |
| Analysts | Hold |
| Price Target | 11.83 (-20.76%) |
| Earnings Date | Feb 26, 2026 |
About VTRS
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CN... [Read more]
Financial Performance
In 2025, Viatris's revenue was $14.30 billion, a decrease of -2.98% compared to the previous year's $14.74 billion. Losses were -$3.51 billion, 454.2% more than in 2024.
Financial StatementsAnalyst Forecast
According to 6 analysts, the average rating for VTRS stock is "Hold." The 12-month stock price target is $11.83, which is a decrease of -20.76% from the latest price.
News
AI Is Sliding and Everything Else Has Run Up. Here Are 6 Stocks That Look Like Buys.
It can seem like a nothing-to-buy market. But there are solid stocks out there.
Viatris Inc. (VTRS) Q4 2025 Earnings Call Transcript
Viatris Inc. (VTRS) Q4 2025 Earnings Call Transcript
Viatris forecasts 2026 profit below estimates on India manufacturing woes
Drugmaker Viatris forecast annual profit below analysts' expectations on Thursday, after a fire at one of its major plants in India disrupted operations.
Viatris Reports Fourth-Quarter and Full-Year 2025 Financial Results
Reports Fourth-Quarter Total Revenues of $ 3.7B and Full-Year 2025 Total Revenues of $ 14.3B Meets or Exceeds 2025 Financial Guidance Across All Key Metrics[1] Returns More Than $1B to Shareholders in...
Viatris Maintains Dividend Policy for 2026 and Announces Quarterly Dividend
PITTSBURGH, Feb. 26, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that on February 23, 2026, its Board of Directors approved a 2026 dividend policy of 48 cents ($0.48) per share an...
FDA Accepts Viatris Supplemental New Drug Application for MR-141 (Phentolamine Ophthalmic Solution 0.75%) for the Treatment of Presbyopia
FDA PDUFA Goal Date Set for October 17, 2026 PITTSBURGH, Feb. 25, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administrat...
Viatris: Deep-Value Pharma With Emerging Growth Catalysts And Strong Cash Generation
Upcoming launches between 2026–2027, including fast-acting meloxicam, cenerimod, and selatogrel, could support a return to mid-single-digit sales growth and improve margins. With FCF yield above 10% a...
Mapi Pharma to Host Virtual KOL Event to Discuss Glatiramer Acetate Once a Month Depot for Primary Progressive Multiple Sclerosis, on March 3, 2026
NESS ZIONA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Mapi Pharma Ltd., a fully integrated, late-stage clinical development biopharmaceutical company focused on introducing innovative long-acting depo...
Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks With Over 3% Dividend Yields
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a high...
Dividend Income: Lanny's December 2025 Summary
In December, we received a dividend income total of $8,010.54. The retirement accounts are composed of HSA investments, ROTH and traditional IRAs, as well as our work 401(k) accounts. In total, divide...
Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026
PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced it will report fourth quarter and full year 2025 financial results on Thursday, Febru...
Viatris Appoints Matthew J. Maletta as Chief Legal Officer
Brian Roman to Leave the Company After More Than 20 Years of Exemplary Service; Will Remain Advisor Through Transition Period PITTSBURGH, Feb. 3, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) anno...
Viatris Expands Innovative Portfolio in Cardiovascular Diseases with the Company's First Launch of Inpefa® (Sotagliflozin) for the Treatment of Heart Failure
Builds on Viatris' Scientific Leadership and Commercial Legacy in Cardiovascular Diseases PITTSBURGH, Jan. 20, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today anno...
Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Viatris Inc. (VTRS) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer
PITTSBURGH, Jan. 8, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) announced today that Lara Ramsburg has been appointed Chief People and Corporate Affairs Officer. As part of Viatris' ongoing trans...
Mapi Pharma is Seeking New Partnerships for Long-Acting Depot Drugs of Peptides for Self Administration
Management to Participate in the 44th Annual J.P. Morgan Healthcare Conference Management to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Viatris Provides Pipeline Update on Four Regulatory Milestones
Receives U.S. Food and Drug Administration (FDA) Approval for Generic Version of Sandostatin® LAR Depot (Octreotide Acetate for Injectable Suspension) U.S. FDA Accepts New Drug Application for Low Dos...
Viatris to Present at the 44th Annual J.P. Morgan Healthcare Conference
PITTSBURGH , Dec. 17, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will present at the 44th Annual J.P. Morgan Healthcare Conference ...
Viatris Announces Agreement to Monetize its Equity Stake in Biocon Biologics Limited
Viatris to Receive $400 Million in Cash and $415 Million in Equity Shares of Biocon Limited Transaction Accelerates the Expiration of Biosimilars Non-Compete Restrictions PITTSBURGH , Dec. 6, 2025 /PR...
Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Viatris Inc. (VTRS) Presents at Evercore 8th Annual Healthcare Conference Transcript
Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Viatris Inc. (VTRS) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript
Viatris to Participate in Upcoming Investor Conferences
PITTSBURGH , Nov. 24, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the Company will participate in two upcoming healthcare conferences in Decembe...
Viatris Inc. (VTRS) Presents at Jefferies London Healthcare Conference 2025 Transcript
Viatris Inc. ( VTRS) Jefferies London Healthcare Conference 2025 November 18, 2025 6:30 AM EST Company Participants Scott Smith - CEO & Director Theodora Mistras - Chief Financial Officer Philippe Ma...
Viatris Recognized as One of the Fortune World's Best Workplaces™ in 2025
PITTSBURGH , Nov. 13, 2025 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS) today announced that it has been recognized as one of the Fortune World's Best Workplaces™ in 2025 . The list of 25 global lead...
Viatris Inc. (VTRS) Presents at UBS Global Healthcare Conference 2025 Transcript
Viatris Inc. ( VTRS) UBS Global Healthcare Conference 2025 November 11, 2025 8:45 AM EST Company Participants Theodora Mistras - Chief Financial Officer Conference Call Participants Ashwani Verma - U...